Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets (Current Period Unaudited)

v3.23.2
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets    
Cash and cash equivalents $ 6,196 $ 7,082
Accounts receivable 104 12
Lease receivable, current portion 0 15,527
Inventory 631 278
Assets held for sale 0 47
Prepaid expenses and other current assets 183 263
Total current assets 7,114 23,209
Non-current assets    
Property, plant and equipment, net 11,951 7,343
Intellectual property, net 371 461
Investment in LINICO 2,000 2,000
Other assets 445 489
Total non-current assets 14,767 10,293
Total assets 21,881 33,502
Current liabilities    
Accounts payable 776 1,075
Accrued expenses 1,986 1,780
Building purchase deposit 0 3,250
Lease liability, current portion 316 307
Note payable, current portion 34 5,899
Total current liabilities 3,112 12,311
Non-current liabilities    
Lease liability, non-current portion 118 275
Note payable, non-current portion 2,908 0
Total liabilities 6,138 12,586
Commitments and contingencies (see Note 13)
Stockholders’ equity    
Common stock; $0.001 par value; 200,000,000 shares authorized; 84,018,082 and 83,507,450, shares issued and outstanding as of June 30, 2023, respectively and 79,481,751 shares issued and outstanding as of December 31, 2022 84 79
Additional paid-in capital 224,878 220,114
Accumulated deficit (208,642) (199,277)
Treasury stock, at cost; common shares: 510,632 and nil as of June 30, 2023 and December 31, 2022, respectively (577) 0
Total stockholders’ equity 15,743 20,916
Total liabilities and stockholders’ equity $ 21,881 $ 33,502